Acurx Pharmaceuticals, Inc. (ACXP) — Financial statements
Income statement, balance sheet, and cash flow for Acurx Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 1,835↑33848.2% | 5↓10.6% | 6↑27.1% | 5↑134.2% | 2 | |
| General & Administrative Expenses | 6,257↑71831.1% | 9↑1.9% | 9↑16.3% | 7↓32.0% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6,257↑71831.1% | 9↑1.9% | 9↑16.3% | 7↓32.0% | 11 | |
| Other Expenses | -8,084 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 8↓42.6% | 14↓3.3% | 15↑20.5% | 12↓5.6% | 13 | |
| Total Costs & Expenses | 8↓42.6% | 14↓3.3% | 15↑20.5% | 12↓5.6% | 13 | |
| Operating Results | ||||||
| Operating Income | -8↑42.6% | -14↑3.3% | -15↓20.5% | -12↑5.6% | -13 | |
| Depreciation & Amortization | 0.00↓100.0% | 14 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -8 | 0.00↑100.0% | -15↓20.5% | -12↑5.6% | -13 | |
| EBIT | -8↑42.6% | -14↑3.3% | -15↓20.5% | -12↑5.6% | -13 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.13 | 0.00 | 0.00 | 0.00↓100.0% | 0.07 | |
| Income Before Tax | -8↑43.5% | -14↑3.3% | -15↓20.5% | -12↑5.1% | -13 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -8↑43.5% | -14↑3.3% | -15↓20.5% | -12↑5.1% | -13 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -8↑43.5% | -14↑3.3% | -15↓20.5% | -12↑5.1% | -13 | |
| Bottom-Line Net Income | -8↑43.5% | -14↑3.3% | -15↓20.5% | -12↑5.1% | -13 | |
| EPS (Basic) | -5.32↑69.8% | -17.59↑23.6% | -23.01↓2.9% | -22.36↑10.4% | -24.96 | |
| EPS (Diluted) | -5.32↑69.8% | -17.59↑23.6% | -23.01↓2.9% | -22.36↑10.4% | -24.96 | |
| Weighted Average Shares | 1↑76.0% | 0.85↑34.4% | 0.63↑17.2% | 0.54↑5.9% | 0.51 | |
| Weighted Average Diluted Shares | 1↑76.0% | 0.85↑34.4% | 0.63↑17.2% | 0.54↑5.9% | 0.51 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.